A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF DATO-DXD VERSUS INVESTIGATOR¿S CHOICE OF CHEMOTHERAPY IN PARTICIPANTS WITH INOPERABLE OR METASTATIC HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER WHO HAVE BEEN TREATED WITH ONE OR TWO PRIOR LINES OF SYSTEMIC CHEMOTHERAPY (TROPION BREAST01)
- Registry ID
- D9268C00001
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ASTRAZENECA AB
- Start date
- 2022-08-11
- Last update
- 2021-09-16
Conditions
- HER2 NEGATIVE METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BRCA ASSOCIATED BREAST CANCER
Related clinical trials
- AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY TO EVALUATE PATRITUMAB
DERUXTECAN MONOTHERAPY VERSUS TREATMENT OF PHYSICIAN¿S CHOICE IN
HORMONE RECEPTORPOSITIVE, HER2-NEGATIVE UNRESECTABLE LOCALLY ADVANCED
OR METASTATIC BREAST CANCER (HERTHENA-BREAST04)
- AN OPEN-LABEL, RANDOMIZED PHASE 3 STUDY OF MK-2870 AS A SINGLE AGENT AND
IN COMBINATION WITH PEMBROLIZUMAB VERSUS TREATMENT OF PHYSICIAN¿S CHOICE
IN PARTICIPANTS WITH HR+/HER2 UNRESECTABLE LOCALLY ADVANCED OR
METASTATIC BREAST CANCER
- XENERA-1: A MULTI-CENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMISED PHASE II TRIAL TO COMPARE EFFICACY OF XENTUZUMAB IN COMBINATION WITH EVEROLIMUS AND EXEMESTANE VERSUS EVEROLIMUS AND EXEMESTANE IN POST-MENOPAUSAL WOMEN WITH HR+ / HER2-METASTATIC BREAST CANCER AND NON-VISCERAL DISEASE
- A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF TASELISIB PLUS FULVESTRANT VERSUS PLACEBO PLUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE AND HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE DISEASE RECURRENCE OR PROGRESSION DURING OR AFTER AROMATASE INHIBITOR THERAPY
View on source registry